Lexicon Pharmaceuticals | LXRX - Ativo Circulante





Ativo Circulante Alterar Data
Abbott USD 26B 1.16B 2025-12
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Akebia Therapeutics USD 252.96M 5.38M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Illumina USD 3.29B 493M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
J&J USD 55.62B 1.01B 2025-12
Lexicon Pharmaceuticals USD 101.9M 20.63M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Novartis USD 30.46B 2.26B 2025-12
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Thermo Fisher Scientific USD 28.71B 6.41B 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12